Key questions
Which OTC-like drugs in Japan face an extra patient charge?
Patients will pay an extra charge on 77 OTC-like ingredients, about ¥90 bn a year, according to KIRA's 2026 trends and outlook [Jiho OTC 2026].
Source: Jiho OTC 2026, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook
How much of Japan's drug pipeline is run by foreign firms?
Foreign firms run 73% of Japan's drug pipeline, according to KIRA's 2026 trends and outlook [PhRMA Apr 2026].
Source: PhRMA Apr 2026, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook
How many products have used Japan's rapid-introduction premium?
Only 7 products had used the rapid-introduction premium by 2026, against 28 new drug-loss items, according to KIRA's 2026 trends and outlook [ISPOR 2026].
Source: ISPOR 2026, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook
How big could Japan's prescription drug market be in FY2030 in KIRA's open-market future?
In KIRA's open-market future for FY2030 (a scenario, not a forecast), the prescription drug market reaches about ¥13.1 tn at the midpoint of the range, according to KIRA's 2026 trends and outlook.
Source: Kira estimates, 2030 · KIRA report: Japan prescription drugs 2026: trends and outlook
What is the outlook for Japan's prescription drug market to FY2030?
KIRA estimates Japan's FY2030 prescription drug market at ¥11.0-13.6 tn, with ¥11-13 tn as the planning range, against an industry baseline of ¥11.9 tn, according to KIRA's 2026 trends and outlook.
Source: Kira estimates, 2030 · KIRA report: Japan prescription drugs 2026: trends and outlook
Which generic drug makers in Japan are consolidating?
Sawai and Nichi-Iko agreed in September 2025 to consolidate 15 ingredients between them, one of several generic realignments, according to KIRA's 2026 trends and outlook [Jiho generics 2025].
Source: Jiho generics 2025, 2025 · KIRA report: Japan prescription drugs 2026: trends and outlook
What is the operating margin of pharmaceutical wholesalers in Japan?
The operating margin of pharmaceutical wholesalers was 1.04% in FY2025 (flash), down from 1.11% in FY2024, according to KIRA's 2026 trends and outlook [Jiho wholesale 2026].
Source: Jiho wholesale 2026, 2025 · KIRA report: Japan prescription drugs 2026: trends and outlook
How much do pharmacies earn from drugs and dispensing fees in Japan?
Pharmacies earned ¥6.06 tn from drugs and ¥2.33 tn from dispensing fees, while the gap between list and purchase price is about 5% on average, according to KIRA's 2026 trends and outlook [MHLW 2025 dispensing].
Source: MHLW 2025 dispensing, 2025 · KIRA report: Japan prescription drugs 2026: trends and outlook
How big is Japan's prescription drug market?
Japan's prescription drug market reached a record ¥11.8 tn at NHI prices in FY2025, up 3.1%, according to KIRA's 2026 trends and outlook [IQVIA May 2026].
Source: IQVIA May 2026, 2025 · KIRA report: Japan prescription drugs 2026: trends and outlook
How much of Japan's off-patent product range has been cut in price?
95% of off-patent biologic products had their price cut in FY2026, against 69% of small molecules, according to KIRA's 2026 trends and outlook [GlobalData 2026].
Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook
How many items were repriced or kept price in the April 2026 revision?
In the April 2026 revision, 653 new drugs kept their price and 704 unprofitable products were repriced up, according to KIRA's 2026 trends and outlook [Jiho 2026].
Source: Jiho 2026, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook
How wide is the gap between list price and purchase price for drugs in Japan?
The average gap between list and purchase price fell from 7% in FY2023 to 4.8% in FY2026, according to KIRA's 2026 trends and outlook [Jiho Dec 2025].
Source: Jiho Dec 2025, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook
How many new molecular entities approved in the US or EU are missing in Japan?
143 new molecular entities approved in the US or EU in 2016-20 were still unapproved in Japan, and 86 of them had no Japanese development, according to KIRA's 2026 trends and outlook [PMDA 2023].
Source: PMDA 2023, 2023 · KIRA report: Japan prescription drugs 2026: trends and outlook
How many prescription drug items were on limited shipment or suspended in Japan?
About 12% of listed prescription drug items were on limited shipment or suspended in August 2026, according to KIRA's 2026 trends and outlook [MHLW 2026 supply].
Source: MHLW 2026 supply, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook
Which prescription drug trend has the biggest impact on the FY2030 market in Japan?
Annual price cuts and protection for new drugs score 5 of 5 on impact and pace in KIRA's view, with the April 2026 cut at -4.02% and an FY2027 off-year revision planned, according to KIRA's 2026 trends and outlook.
Source: Kira estimates, 2026 · KIRA report: Japan prescription drugs 2026: trends and outlook
More on Prescription drugs in Japan